TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
1.1 GLOBAL PEGYLATED DRUGS MARKET, BY MOLECULE 14
1.2 GLOBAL PEGYLATED DRUGS MARKET, BY INDICATION 15
2 Market Introduction
2.1 DEFINITION 16
2.2 SCOPE OF THE STUDY 16
2.3 RESEARCH OBJECTIVE 16
2.4 MARKET STRUCTURE 17
3 Research Methodology
3.1 RESEARCH PROCESS 18
3.2 PRIMARY RESEARCH 19
3.3 SECONDARY RESEARCH 20
3.4 MARKET SIZE ESTIMATION 21
3.5 FORECAST MODEL 22
3.6 LIST OF ASSUMPTIONS 23
4 MARKET DYNAMICS
4.1 INTRODUCTION 24
4.2 DRIVERS 25
4.2.1 INCREASE IN THE PREVALENCE OF CHRONIC DISEASES SUCH AS CANCER 25
4.2.2 GROWING PHARMACEUTICAL INDUSTRY 25
4.2.3 ADVANCEMENT IN THE BIOLOGICS SECTOR 25
4.3 RESTRAINTS 26
4.3.1 ADVERSE DRUG REACTIONS ASSOCIATED WITH PEGYLATED DRUGS 26
4.3.2 DRUG RECALL 26
4.4 OPPORTUNITIES 26
4.4.1 STRONG PIPELINE FOR PEGYLATED DRUGS 26
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS 27
5.1.1 R&D 28
5.1.2 MANUFACTURING 28
5.1.3 DISTRIBUTION & SALES 28
5.1.4 POST-SALES MONITORING 28
5.2 PORTER'S FIVE FORCES MODEL 29
5.2.1 THREAT OF NEW ENTRANTS 30
5.2.2 BARGAINING POWER OF SUPPLIERS 30
5.2.3 BARGAINING POWER OF BUYERS 30
5.2.4 THREAT OF SUBSTITUTES 30
5.2.5 INTENSITY OF RIVALRY 30
6 GLOBAL PEGYLATED DRUGS MARKET, BY MOLECULE
6.1 OVERVIEW 31
6.2 PROTEIN 33
6.3 FAB' FRAGMENT 33
6.4 ENZYME 34
6.5 APTAMER 34
7 GLOBAL PEGYLATED DRUGS MARKET, BY INDICATION
7.1 OVERVIEW 35
7.2 CANCER 37
7.3 GOUT 37
7.4 HEMOPHILIA 38
7.5 HEPATITIS 38
8 GLOBAL PEGYLATED DRUGS MARKET, BY REGION
8.1 OVERVIEW 39
8.2 AMERICAs 41
8.2.1 NORTH AMERICA 43
8.2.2 LATIN AMERICA 45
8.3 EUROPE 46
8.3.1 WESTERN EUROPE 48
8.3.2 EASTERN EUROPE 55
8.4 ASIA-PACIFIC 56
8.4.1 JAPAN 58
8.4.2 CHINA 59
8.4.3 INDIA 60
8.4.4 AUSTRALIA 61
8.4.5 SOUTH KOREA 62
8.4.6 REST OF ASIA-PACIFIC 63
8.5 MIDDLE EAST & AFRICA 64
8.5.1 MIDDLE EAST 66
8.5.2 AFRICA 67
9 COMPETITIVE LANDSCAPE
9.1 INTRODUCTION 68
9.2 MAJOR PEGYLATED DRUGS 70
10 COMPANY PROFILES
10.1 HORIZON THERAPEUTICS PLC 71
10.1.1 COMPANY OVERVIEW 71
10.1.2 FINANCIAL OVERVIEW 71
10.1.3 PRODUCTS/SERVICES OFFERED 72
10.1.4 KEY DEVELOPMENTS 72
10.1.5 SWOT ANALYSIS 73
10.1.6 KEY STRATEGIES 73
10.2 F. HOFFMANN-LA ROCHE LTD 74
10.2.1 COMPANY OVERVIEW 74
10.2.2 FINANCIAL OVERVIEW 74
10.2.3 PRODUCTS/SERVICES OFFERED 75
10.2.4 KEY DEVELOPMENTS 75
10.2.5 SWOT ANALYSIS 75
10.2.6 KEY STRATEGIES 76
10.3 PFIZER INC. 77
10.3.1 COMPANY OVERVIEW 77
10.3.2 FINANCIAL OVERVIEW 77
10.3.3 PRODUCTS/SERVICES OFFERED 78
10.3.4 KEY DEVELOPMENTS 78
10.3.5 SWOT ANALYSIS 79
10.3.6 KEY STRATEGIES 79
10.4 NOVO NORDISK A/S 80
10.4.1 COMPANY OVERVIEW 80
10.4.2 FINANCIAL OVERVIEW 80
10.4.3 PRODUCTS/SERVICES OFFERED 81
10.4.4 KEY DEVELOPMENTS 81
10.4.5 SWOT ANALYSIS 82
10.4.6 KEY STRATEGIES 82
10.5 UCB S.A. 83
10.5.1 COMPANY OVERVIEW 83
10.5.2 FINANCIAL OVERVIEW 83
10.5.3 PRODUCTS/SERVICES OFFERED 84
10.5.4 KEY DEVELOPMENTS 84
10.5.5 SWOT ANALYSIS 85
10.5.6 KEY STRATEGIES 85
10.6 AMGEN, INC. 86
10.6.1 COMPANY OVERVIEW 86
10.6.2 FINANCIAL OVERVIEW 86
10.6.3 Products/Services Offered 87
10.6.4 KEY DEVELOPMENTS 87
10.6.5 KEY STRATEGIES 88
10.7 ASTRAZENECA 89
10.7.1 COMPANY OVERVIEW 89
10.7.2 FINANCIAL OVERVIEW 89
10.7.3 PRODUCTS/SERVICES OFFERED 90
10.7.4 KEY DEVELOPMENTS 90
10.7.5 SWOT ANALYSIS 90
10.7.6 KEY STRATEGIES 91
10.8 MERCK & CO., INC. 92
10.8.1 COMPANY OVERVIEW 92
10.8.2 FINANCIAL OVERVIEW 92
10.8.3 PRODUCTS/SERVICES OFFERED 93
10.8.4 KEY DEVELOPMENTS 93
10.8.5 SWOT ANALYSIS 94
10.8.6 KEY STRATEGIES 94
10.9 TAKEDA PHARMACEUTICAL COMPANY LIMITED 95
10.9.1 COMPANY OVERVIEW 95
10.9.2 FINANCIAL OVERVIEW 95
10.9.3 PRODUCTS/SERVICES OFFERED 96
10.9.4 KEY DEVELOPMENTS 96
10.9.5 SWOT ANALYSIS 96
10.9.6 KEY STRATEGIES 97
10.10 BAYER AG 98
10.10.1 COMPANY OVERVIEW 98
10.10.2 FINANCIAL OVERVIEW 98
10.10.3 PRODUCTS/SERVICES OFFERED 99
10.10.4 KEY DEVELOPMENTS 99
10.10.5 SWOT ANALYSIS 99
10.10.6 KEY STRATEGIES 100
11 APPENDIX
11.1 REFERENCES 101
11.2 RELATED REPORTS 101
